India's Medical Value sector projected to reach $ 13 billion by 2026: Dr Mandaviya

Need to harmonize traditional and modern medicine to combat alarming health problems

Govt. of Arunachal, Sir Ganga Ram Hospital and Religare Enterprises sign an MoU to support the development of the state’s healthcare services

The first such initiative under the MoU will involve establishing a Centre of Excellence for Renal Sciences at the Tomo Riba Institute of Health & Medical Sciences (TRIHMS)

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

DGHS organizes National Webinar on National Organ and Tissue Transplant Organisation

Six engaging sessions focusing on Prevention of Kidney Diseases, Brain Stem Death Declaration, Deceased Donor Management, Prevention of Liver Diseases, Legal Aspects of Organ and Tissue Donation, Eye Donation and Corneal Transplant held as part of the Webinar

CARER collaborates with Wholeleaf to enhance holistic cancer care services

The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being

L V Prasad Eye Institute and Indian Oil sign MoU to provide care to children with eye cancer

The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.

Philips' direct-to-angio stroke pathway demonstrates improved patient outcomes

Economic analysis of cost of Vall d’Hebron University Hospital Stroke Unit shows direct-to-angio stroke pathway can save more than USD 3,000 per patient

Advanced Treatments for Brain Tumors: Secure Procedures Available

Keytruda+ chemotherapy improves overall survival versus chemotherapy alone for unresectable advanced pleural mesothelioma

In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone

Novartis receives European approval for Cosentyx

European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5